Potential GI therapeutic indications for glucagon-like peptide 1 based therapies
| Condition | (potential) Mechanisms | Level of evidence |
|---|---|---|
| Dumping syndrome | Gastric emptying ↓ | Case series67 |
| Functional dyspepsia | Gastric emptying ↓ Gastric acid secretion ↓ | Hypothesised |
| Constipated IBS | Colon circular muscle tone ↓ Visceral sensitivity ↓ | Clinical trials: improved defaecation pattern, pain relief80 91 |
| Short bowel syndrome | Gastric and bowel motility ↓ | Clinical trials: reduced diarrhoea, improved nutritional status93 94 |
| Mucositis and IBD | Inflammatory parameters ↓ Mucosal apoptosis ↓ Mucosa proliferation ↑ | Animal studies: prevention of loss in mucosal mass in experimental mucositis89 97 |
| NAFLD | Weight ↓ Hepatic insulin sensitivity ↑ Hepatic de novo lipogenesis ↓ Fatty acid oxidation ↑ | Clinical trials: reduction in steatosis and steatohepatitis148 155 |
| Cholangiopathies | Cholangiocyte proliferation ↑ Cholangiocyte apoptosis ↓ Bile acid production ↓ | Hypothesised168 |
NAFLD, non-alcoholic fatty liver disease.